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ients with late-acquired ISA versus control subjects with no ISA for BMS (14.3% vs. 7.9%, p  0.54),
AXUS (overall, 8.3% vs. 8.1% p  0.87), or TAXUS slow-release formulation (0% vs. 7.9%, p  0.28).
here was no impact of late-acquired ISA on stent thrombosis.
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487ncomplete stent apposition (ISA) might occur, on the basis
f intravascular ultrasound (IVUS) studies, either at the time of
he initial procedure (early ISA) and persist or resolve; or it
ight develop over time as a result of regional remodeling or
hrombus dissolution (late-acquired ISA) (1). Although con-
idered a criterion for poor stent implantation technique, early
SA has never been implicated in early or late events. Con-
ersely, 2 recent studies—1 a meta-analysis—have implicated
ate-acquired ISA in very late stent thrombosis (2,3). Never-
heless, the clinical consequences of early or late ISA remain
ncertain and controversial.
See page 495
The TAXUS (Boston Scientific, Natick, Massachusetts)
andomized trials and TAXUS-ATLAS studies examined
he performance of paclitaxel-eluting TAXUS Express and
AXUS Liberté stents, respectively, in increasingly com-
lex lesion subtypes. The pooled IVUS substudies of these
tudies represent the largest population of TAXUS-treated
atients with a wide range of lesion characteristics and
ifferent implantation techniques (with or without pre-
ilation). The current analysis uses the combined IVUS
ubset data from these studies to examine the incidence,
redictors, and clinical consequences of early and late ISA in
atients treated with paclitaxel-eluting TAXUS Express
nd TAXUS Liberté and bare-metal Express stents (BMS).
ethods
atient population and protocol. The TAXUS IV, TAXUS
, and TAXUS VI studies were prospective, double blind,
MS-controlled trials in which patients with a single de
ovo native coronary artery lesion were randomly assigned
o treatment with a paclitaxel-eluting stent (PES) or an
therwise identical BMS (Boston Scientific) (4–6). The
AXUS IV and V studies used the TAXUS Express stent
ith the paclitaxel slow-release (commercially available)
ormulation; whereas the TAXUS VI trial used the TAXUS
xpress stent with the moderate-release (not commercially
vailable) formulation. The TAXUS ATLAS WH (Work-
orse), LL (Long Lesion), and DS (Direct Stent) trials were
rospective single-arm studies using the new-generation,
hin-strut TAXUS Liberté stent (Boston Scientific). Both
AXUS WH and LL compared TAXUS Liberté with
AXUS Express historical control subjects from TAXUS
V and V (7), whereas the TAXUS ATLAS DS trial
ompared TAXUS Liberté implantations with and without
re-dilation. Of the 4,184 patients enrolled in the 6 trials,
,580 patients (1,098 PES and 482 BMS) were enrolled in
VUS substudies and were included in the current analyses;
linical sites were selected on the basis of their IVUS
xperience, volume, and willingness to enroll all of their
atients in the IVUS substudy. The IVUS substudy patients sithin each trial gave consent at the time of the index
rocedure for both the index and follow-up IVUS studies.
hey were enrolled until the pre-specified numbers were
btained. The IVUS substudy data from these trials were
nalyzed at a single core laboratory (MedStar Research
nstitute, Washington Hospital Center, Washington, DC)
8), and the angiographic studies were analyzed at a single
ore laboratory (Brigham and Women’s Hospital, Boston,
assachusetts).
Patients returned for angiographic and IVUS studies at 9
onths after the index procedure and then were followed up
ver 2 ensuing years. Major adverse cardiovascular events
MACE) included cardiac death, myocardial infarction
MI), and target vessel revascularization (TVR). Myocardial
nfarction was defined as the electrocardiographic appear-
nce of pathologic Q waves in at least 2 contiguous leads
ssociated with an elevated creatine kinase-myocardial band
raction or an elevated creatine
inase-myocardial band fraction
2 times the upper limit of
ormal in the absence of patho-
ogic Q waves. Target vessel re-
ascularization was defined as an
schemia-driven revascularization
ccurring due to stenosis in the
reated vessel.
Stent thrombosis was defined
ccording to the Academic Re-
earch Consortium definitions
egarding timing and probability
f stent thrombosis (9). Briefly,
tent thrombosis was considered
efinite if confirmed by angiog-
aphy or pathology, probable in
he setting of MI in the territory
f the stent or unexplained death
ithin 30 days of stent implan-
ation, and possible in the setting of unexplained death more
han 30 days after stent implantation. The timing of stent
hrombosis was classified as early (within 30 days), late
between 30 days and 1 year), and very late (1 year) (6).
ngiographic analysis. Two or more angiographic projec-
ions of the stenosis after intracoronary nitroglycerin were
cquired with repetition of identical angiographic projec-
ions of the lesion at the time of follow-up angiography.
ith the contrast-filled injection catheter as the calibration
ource, quantitative coronary angiographic analysis was
erformed with a validated automated edge-detection algo-
ithm (Medis CMS, Leiden, the Netherlands) by a techni-
ian who was unaware of the clinical or IVUS findings and
ho was blinded to the treatment arm. Angiographic
n-stent restenosis was defined as percentage diameter
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BMS  bare-metal stent(s)
ISA  incomplete stent
apposition
IVUS  intravascular
ultrasound
MACE  major adverse
cardiovascular events
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TVR  target vessel
revascularizationtenosis 50%.
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488VUS protocol and analysis. The IVUS imaging was per-
ormed after intracoronary administration of 0.1 to 0.2 mg
itroglycerin with motorized pullback (0.5 mm/s) and
ontemporary, commercial scanners. Images were continu-
usly recorded throughout the stent and at least 5-mm
eference segments distal and proximal to the stent. Images
ere recorded onto s-VHS videotape or onto compact discs
r magneto-optical discs for offline analysis at a single,
ndependent core laboratory by technicians who were un-
ware of treatment assignment or patient outcomes. With
he use of computerized planimetry (TapeMeasure, Indec
ystems, Mountain View, California), stent and lumen
orders were manually traced every 1 mm; intimal hyper-
lasia was calculated as stent-lumen area; and percentage
ntimal hyperplasia volume was calculated as intimal hyper-
lasia volume divided by stent volume with Simpson’s rule.
Incomplete stent apposition was defined as a separation
f at least 1 stent strut from the intimal wall not overlapping
side branch with evidence of blood speckling (indicating
ow). If ISA was noted on the IVUS analysis after stent
mplantation, it was referred to as early ISA; it either
esolved or persisted on follow-up analysis. Late-acquired
SA referred to ISA that was not present on IVUS analysis
fter stent implantation but developed during the follow-up
eriod and was detected on 9-month IVUS analysis.
Table 1. Baseline Characteristics of Patients and Les
Stent-Vessel Wall Apposition
Variable
N
(
Age, yrs 62.
Sex (male) 70
Previous MI 30
CHF 6
Unstable angina 33
Current smoking 18
Diabetes, medically-treated 24
Hypercholesterolemia 72
Hypertension 70
Target lesion vessel location (LAD/non-LAD) 43
Pre-intervention
Lesion length, mm 1
Reference vessel, mm
Minimum lumen diameter, mm
Calciﬁcation 26
Bend (45°) 22
Vessel tortuosity 9
Pre-procedure thrombus 4
Aneurysmal appearance 2
Use of glycoprotein IIb/IIIa inhibitors 34
Pre-dilation 68
Multiple stent 17
Values are mean  SD or %.CHF congestive heart failure; ISA incomplete stent apposition; LADtatistical methods. Baseline, post-procedural, and follow-up
ata were summarized with descriptive statistics and presented as
roportions (percentage, count/sample size) or mean  SD.
ategorical variables were compared between groups with chi-
quare or Fisher exact test, as appropriate. Continuous variables
ere compared between groups with 2-tailed, unpaired t tests.
The Kaplan-Meier product-limit method was employed to
ssess time-to-event end points. Kaplan-Meier event rates and
urves are shown. The log-rank test was employed to compare
urvival curves between patients with and without early incom-
lete apposition at 9 months after the index procedure and
etween patients with and without late-acquired incomplete
pposition at 2 years after the 9-month IVUS follow-up.
To determine predictors of early and late-acquired in-
omplete apposition, all covariates were modeled by multi-
ariate analysis with stepwise procedure in a logistic regres-
ion model. The significance level for entry/exit was set at
.10. No corrections were made for multiple comparisons.
Statistical significance was accepted at a value of p  0.05.
esults
ncidence, patient baseline characteristics, and predictors of
arly ISA. Overall, 96 cases of early ISA were identified: 26
7.2%) BMS, 35 (9.7%) TAXUS Express (p  0.28 vs.
With Early ISA Versus Those With Complete
y ISA
,104)
Early ISA
(n  96) p Value
0.61 64.40 9.90 0.0352
/1,104) 71.9 (69/96) 0.82
/1,104) 40.6 (39/96) 0.0376
1,103) 7.3 (7/96) 0.65
/1,104) 29.2 (28/96) 0.42
/1,098) 26.0 (25/96) 0.64
/1,104) 33.3 (32/96) 0.09
/1,070) 77.4 (72/93) 0.68
/1,050) 71.3 (67/94) 1.00
/1,101) 38.5 (37/96) 0.45
7.89 18.18 9.34 0.0131
0.47 3.02 0.56 0.0001
0.34 1.03 0.41 0.0001
/1,096) 41.7 (40/96) 0.0029
/1,096) 35.4 (34/96) 0.0053
/1,095) 11.5 (11/96) 0.46
1,096) 4.2 (4/96) 1.00
1,095) 6.3 (6/96) 0.0330
/1,104) 44.8 (43/96) 0.0442
/1,104) 76.0 (73/96) 0.13
/1,104) 24.0 (23/96) 0.12ions
o Earl
n  1
03 1
.3 (776
.0 (331
.0 (66/
.1 (365
.2 (200
.9 (275
.8 (779
.4 (739
.0 (473
6.06
2.77
0.87
.9 (295
.3 (244
.1 (100
.3 (47/
.3 (25/
.1 (377
.3 (754
.3 (191left anterior descending coronary artery; MImyocardial infarction.
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489MS), and 35 (7.3%) TAXUS Liberté stents (p  0.21 vs.
AXUS Express, and p  1.00 vs. BMS).
Baseline and procedural characteristics of patients with
arly ISA are summarized in Table 1. Patients with early
SA were slightly older than those with fully apposed
tents and were more likely to have had prior MI or to be
reated with adjunctive glycoprotein IIb/IIIa inhibitors.
hen compared with lesions with complete stent-vessel
all apposition, lesions associated with early ISA were:
) significantly longer; 2) more likely to be calcified, have
n aneurysmal appearance, and be located at a bend point
n the vessel; and 3) in larger vessels with a greater
re-intervention minimal lumen diameter. Accordingly,
he post-procedural mean stent area was significantly
arger in patients with early ISA (8.73  2.43 mm2)
ersus those with well-apposed stents (7.67  2.41 mm2,
 0.0001).
Multivariate analysis was performed on the pooled
AXUS and BMS pre-intervention dataset to determine
he risk factors for early ISA (Table 2). The analysis
evealed that aneurysmal appearance of the target lesions,
arger vessels, lesion calcification, use of glycoprotein IIb/
IIa blockers, patient age, and longer lesions were indepen-
ent predictors of early ISA.
-month clinical and IVUS outcomes of patients with early ISA.
t 9-month follow-up, stents with early ISA developed
ignificantly less intimal hyperplasia as compared with
ompletely apposed BMS (21.5  14.8% vs. 32.7  15.2%,
 0.001) and TAXUS stents (8.6  10.0% vs. 13.9 
1.9%, p  0.003).
The ISA persisted at 9-month follow-up in 39% of the
MS-treated and 47% of the TAXUS-treated patients. The
MS with persistent ISA had similar amounts of intimal
yperplasia compared with those with resolved ISA (19.0
0.4% vs. 23.3 17.5%, p 0.5). However, TAXUS stents
ith persistent ISA tended to have less intimal hyperplasia
ompared with those with resolved ISA (5.7  8.4% vs.
1.2  10.7%, p  0.0679).
The MACE rates at 9-month follow-up were similar for
MS with versus without early ISA (3.8% vs. 15.2%,
Table 2. Multivariate Predictors of Early ISA
Predictors Odds Ratio p Value
Aneurysmal appearance 3.10 0.0213
Minimum lumen diameter 2.57 0.0041
Reference vessel 1.93 0.0074
Calciﬁcation 1.72 0.0180
Use of glycoprotein IIb/IIIa inhibitors 1.72 0.0149
Age 1.02 0.0236
Lesion length 1.02 0.05
ISA incomplete stent apposition.og-rank p  0.13) as well as for TAXUS stents with versus nithout early ISA (11.6% vs. 8.8%, log-rank p  0.45).
here were no episodes of definite/probable stent throm-
osis in patients receiving BMS, whether stents were
ell-apposed or associated with early ISA. Similarly, pa-
ients treated with TAXUS stents also had similar rates of
efinite/probable stent thrombosis, whether stents were
ell-apposed or associated with early ISA (1.5% and 0.6%,
espectively, long-rank p  0.45).
ncidence, patient characteristics, and predictors of late-
cquired ISA. Late-acquired ISA was identified in only 36
atients: 7 (2.7%) BMS, 17 (3.1%) TAXUS stents with
aclitaxel slow-release formulation (TAXUS Express and
AXUS Liberté combined), and 12 (15.4%) TAXUS stents
ith paclitaxel moderate-release formulation (not commer-
ially available). The rate of late-acquired ISA with the
AXUS moderate-release stent was significantly higher
ompared with both the BMS (p  0.0001) and the
AXUS slow-release stent (p  0.0001). There was no
ifference in the incidence of late-acquired ISA between
AXUS SR stents versus BMS (p  0.23). The TAXUS
iberté stent, however, had the lowest rate of late-acquired
SA (1.8%) as compared with the TAXUS Express slow-
elease stent (5.3%, p  0.0391).
Baseline patient and lesion characteristics were relatively
imilar for patients with versus without late-acquired ISA
Table 3). Compared with patients with completely apposed
tents, patients with late-acquired ISA were younger and
ore frequently had a history of prior MI.
Multivariate analysis was performed on the pooled
AXUS and BMS data to determine the risk factors for
ate-acquired ISA. The analysis revealed that the
oderate-release formulation of the TAXUS stent was
he strongest predictor of late-acquired incomplete ap-
osition, followed by previous MI and patient age (Table
). When multivariate analysis was performed excluding
he moderate-release formulation (not commercially
vailable), patient age was the only predictor of late-
cquired ISA; however, the number of patients with
ate-acquired ISA was small.
ngiographic and IVUS outcomes in patients with and without
ate-acquired ISA at 9-month follow-up. At 9-month follow-
p, in-stent late loss was significantly less in patients with
ate-acquired ISA as compared with those with well-
pposed stents. In patients with late-acquired ISA, intimal
yperplasia was also significantly less and mean lumen
rea was significantly larger as compared with patients
ith fully apposed BMS or TAXUS (Table 5). There
ere no instances of angiographic in-stent restenosis in any
f the 36 patients with late-acquired ISA—whether BMS
r TAXUS.
In a comparison of patients with persistent early ISA with
hose with late-acquired ISA, there were similar amounts of
eointimal hyperplasia in both BMS (19.0  10.4% vs.
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4901.9  7.8%, p  0.54) and TAXUS stents (5.7  8.4% vs.
.9  7.0%, p  0.9).
ong-term clinical outcomes in patients of late-acquired
SA. Two years after the 9-month IVUS follow-up, MACE
ates were similar in patients with versus without late-
cquired ISA in BMS (14.3% vs. 7.9%, log rank p  0.54),
AXUS stents (overall, 8.3% vs. 8.1%, p  0.87), or
AXUS stents with only the slow-release formulation (0%
s. 7.9%, p  0.28). Event-free survival curves are shown in
igure 1. There were no incidences of definite/probable
tent thrombosis in either BMS or TAXUS-treated patients
ith late-acquired ISA. Conversely, there were 2 incidences
f definite/probable stent thrombosis in the BMS group
0.5%) and 3 in the TAXUS group (0.5%) with complete
tent-vessel wall apposition.
Table 3. Baseline Characteristics of Lesions and Pat
Stent-Vessel Wall Apposition at 9-Month Follow-Up
Variable
No Late
(n
Age, yrs 62.50
Sex (male) 70.
Previous MI 30.
CHF 6.
Unstable angina 32.
Current smoking 20.
Diabetes, med-treated 25.
Hypercholesterolemia 73.
Hypertension 69.
Target lesion vessel location (LAD/non-LAD) 43.
Pre-intervention
Lesion length, mm 15.89
Reference vessel, mm 2.80
Minimum lumen diameter, mm 0.89
Calciﬁcation 28.
Bend (45°) 21.
Vessel tortuosity 9.
Pre-procedure thrombus 4.
Aneurysmal appearance 2.
Post-procedure IVUS MSA, mm2 7.74
Use of glycoprotein IIb/IIIa inhibitors 36.
TAXUS moderate-release 7.
Multiple stents 17.
Values are % or mean SD.
MSAminimum stent area; other abbreviations as in Table 1.
Table 4. Multivariate Predictors of Late-Acquired ISA
Predictors Odds Ratio p Value
TAXUS moderate-release 8.5 0.0001
Previous MI 1.99 0.0482
Age 0.95 0.0045pISA incomplete stent apposition; MImyocardial infarction.linical outcomes in patients with any ISA, regardless of stent
ype. Finally, when patients with any ISA in any stent
combining BMS and TAXUS)—whether early and re-
olved, early and persistent, or late-acquired—were com-
ared with patients with no ISA at any time point, there was
ignificantly lower MACE in patients with ISA (15.0%)
ompared with no ISA (24.2%, log rank p  0.03),
lthough stent thrombosis rates were similar in the 2
roups (0.8% vs. 0.8%, log rank p  0.99). Furthermore
nd again combining BMS and TAXUS stents, there
ere no differences in MACE rates for patients with
arly ISA (17.1%) versus no early ISA, late ISA (16.8%)
ersus no late ISA, and late-acquired ISA (9.4%) versus
o late-acquired ISA.
iscussion
he principal finding in this study is that routinely
etected ISA (whether early or late) is a relatively
ncommon phenomenon after either BMS or TAXUS
low-release stent implantation and, when identified
outinely, has little clinical significance. Indeed, in the 96
With Late-Acquired ISA Versus Those With Complete
ired ISA
7)
With Late-Acquired ISA
(n  36) p Value
7 58.03 9.73 0.0129
847) 86.1 (31/36) 0.06
847) 47.2 (17/36) 0.0410
47) 8.3 (3/36) 0.49
847) 25.0 (9/36) 0.32
842) 22.2 (8/36) 1.00
847) 19.4 (7/36) 0.56
823) 82.9 (29/35) 0.35
802) 71.4 (25/35) 0.85
845) 38.9 (14/36) 0.61
(840) 17.68 7.93 (36) 0.18
(843) 2.84 0.49 (36) 0.60
(843) 0.87 0.44 (36) 0.81
842) 16.7 (6/36) 0.13
842) 27.8 (10/36) 0.41
41) 2.8 (1/36) 0.24
42) 5.6 (2/36) 0.66
41) 5.6 (2/36) 0.26
(778) 7.89 2.23 (33) 0.70
847) 38.9 (14/36) 0.73
47) 33.3 (12/36) 0.0001
847) 22.2 (8/36) 0.37ients
-Acqu
 84
 10.5
7 (599/
1 (255/
3 (53/8
9 (279/
1 (169/
7 (218/
6 (606/
1 (554/
7 (369/
 7.93
 0.47
 0.34
6 (241/
5 (181/
6 (81/8
3 (36/8
6 (22/8
 2.27
1 (306/
8 (66/8
0 (144/atients with early ISA, there was no impact on 9-month
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491ates of restenosis or stent thrombosis. Furthermore, in
he 36 patients with late-acquired ISA, there was no
mpact on MACE or stent thrombosis over the ensuing 2
ears. If anything, when BMS and TAXUS stents with
ny type of ISA (i.e., any early or late ISA) were
ompared with stents without any ISA, MACE rates
ere lower in patients with ISA than in those with no
SA, although stent thrombosis rates were similar, sug-
esting a reduced rate of revascularization in ISA patients
onsistent with previous reports of less intimal hyperpla-
ia in the presence of ISA (10,11).
Figure 1. Kaplan-Meier Analysis of MACE and ST
Kaplan-Meier analysis of major adverse cardiovascular events (MACE) and sten
Table 5. Nine-Month Angiographic and IVUS Outcome
Variable
No Late-Acquired IS
(n  847)
Angiographic
% DS in-stent 24.40 20.05 (829
Late loss in-stent, mm 0.57 0.56 (826)
IVUS
% IH volume, mm3 18.61 15.29 (784
Mean LA, mm2 6.33 2.28 (784)
DS diameter stenosis; IH intimal hyperplasia; ISA incomplete stacquired incomplete stent apposition versus complete apposition. ARC  Academicarly ISA. Nakamura et al. (12) initially demonstrated early
SA in 4 of 63 (6.3%) patients undergoing stent implanta-
ion with Palmaz-Schatz stents. In more recent studies the
ncidence of early ISA has been similar in BMS (range 8%
o 15%) and DES (range 7% to 18%) (10,11,13,14). Early
SA is technique-related and dependent on device sizing
15). On the one hand, retrospective analyses of patients
eveloping early stent thrombosis have implicated ISA as 1
f the predisposing factors (14,16–19). On the other hand,
tudies with post-implantation and follow-up IVUS have
emonstrated that early ISA has no bearing on either
bosis (ST) for patients with bare-metal stent (BMS) and TAXUS stent late-
atients With and Without Late-Acquired ISA
With Late-Acquired ISA
(n  36) p Value
18.41 13.99 (36) 0.08
0.34 0.47 (36) 0.0143
9.12 9.57 (35) 0.0003
7.44 2.55 (35) 0.0053
osition; IVUS intravascular ultrasound; LA lumen area.t throms in P
A
)
)Research Consortium; IVUS  intravascular ultrasound.
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492estenosis or thrombosis, regardless of whether the ISA
esolved or persisted (10,11,13,14).
In the current analysis the incidence of early ISA was
.0% with no significant differences between BMS and
AXUS stents, similar to previous studies. Predictors of
arly ISA included an aneurysmal appearance of the target
esion, larger vessels, lesion calcification, use of glycoprotein
Ib/IIIa blockers, patient age, and longer lesions. These
ndings are consistent with previous reports demonstrating
igher frequency of early ISA with increasing lesion com-
lexity. Also as in previous prospective reports, the presence
f early ISA had no impact on 9-month clinical events.
atients treated with BMS or TAXUS stents had similar
ates of overall MACE and, even more importantly, stent
hrombosis, regardless of whether or not the stent was
ell-apposed to the vessel wall. Additionally stents with
ncomplete stent apposition were associated with less inti-
al hyperplasia at 9-month follow-up than stents with
omplete vessel wall apposition for both BMS (21.5 
4.8% vs. 32.7  15.2%, p  0.001) and TAXUS stents
8.6  10.0% vs. 13.9  11.9%, p  0.003).
With regard to resolved versus persistent ISA, patients
ith persistent ISA had similar amounts of neointimal
yperplasia when treated with BMS; however, there was a
onsignificant trend toward less neointimal hyperplasia in
atients with persistent ISA after TAXUS stent implanta-
ion. This finding is consistent with a recent analysis of
irolimus-eluting stents (SES) demonstrating increased tis-
ue hyperplasia in patients with complete resolution of ISA
ompared with those with persistent ISA (1.7  0.9 mm2
esolved vs. 0.5  1.5 mm2 persistent, p  0.006) (11). In
comparison of patients with resolved versus persistent
SA, there were no significant differences in 9-month
linical events for patients treated with either BMS or
AXUS stents.
ate-acquired ISA. Previous studies have reported that late-
cquired ISA occurred in approximately 4% to 5% of cases
fter BMS in patients without acute myocardial infarction
AMI) (20,21), 5% to 15% of cases after BMS in patients
ith AMI (22) or after DES in patients without AMI
10,14,23,24), and as high as 35% after DES in patients
ith AMI (22). Predictors of late-acquired ISA have
ypically included treatment of chronic total occlusions,
irectional atherectomy before stent implantation, stent
ength, AMI, absence of diabetes, and implantation of DES
10,13,14,24–26).
In the current study late-acquired ISA occurred in 36
atients: 2.7% in BMS, 3.1% in TAXUS-SR, and 15.4% in
AXUS-MR. After adjustment for baseline variables, the
nly consistent pre-procedural predictors of late-acquired
SA were the use of the moderate-release platform (not
ommercially available), previous MI, and patient age.
urthermore, excluding the moderate-release formulation,he only independent predictor of late-acquired ISA was natient age; however, patients and lesions with most of the
reviously reported risk factors for late-acquired ISA (i.e.,
hronic total occlusions, directional atherectomy before
tent implantation, and AMI) were excluded from the
AXUS and TAXUS ATLAS studies. Late-acquired ISA
eemed to result from positive vessel wall remodeling
ithout proportional abluminal neointimal tissue growth,
imilar to previous studies (1,10,13,14,21,22,24,26).
Over a 2-year period after the scheduled 9-month
ollow-up with angiographic and IVUS studies, routinely
etected late-acquired ISA was not associated with any
ACE events. No death, MI, target lesion/vessel revascu-
arization, or stent thrombosis occurred in any of the 17
atients with late-acquired ISA who were treated with
AXUS slow-release stents. This finding is also consistent
ith previous studies in BMS, SES, and PES demonstrat-
ng no increase in clinical events relating to late-acquired
SA (10,13,14,20). Ako et al. (13) reported on 7 patients
ith late-acquired ISA after SES implantation and followed
p for 12 months; no patient had a clinical event over the
uration of follow-up. Hong et al. (20) followed 54 patients
ith late-acquired ISA after BMS implantation and found
o impact on clinical events over 3 years of follow-up. The
ame investigators subsequently examined 82 patients
ith 85 DES-treated lesions (71 SES and 14 PES) and
ate-acquired ISA. They found that, over a 10-month
ollow-up period, no patient developed a clinical event
10). Additionally, after 31  6 months, 1.3% of 80
atients (83 lesions) with late-acquired ISA had experi-
nced AMI, compared with 0.4% of 452 patients (588
esions) without late-acquired ISA (27). Finally, in their
nalysis of the TAXUS II trial, Tanabe et al. (14) found
o relation between late-acquired ISA and clinical events
n patients undergoing TAXUS (either SR or MR)
mplantation.
However, there are other reports implicating late-
cquired ISA in late and very late stent thrombosis. For
xample, Siqueira et al. (26) reported on 10 patients with
ate-acquired ISA compared with 172 patients with no ISA
nd found a 20% rate of stent thrombosis in patients with
ate-acquired ISA compared with 0% with no ISA (p 
.002). Additionally, Cook et al. (2) demonstrated ISA in
7% (10 of 13) of DES-treated patients presenting with
ery late stent thrombosis (1 year after implantation)
ompared with 12% (17 of 144) of control cases without
ES thrombosis. Finally, in a recent meta-analysis, Hassan
t al. (3) analyzed 17 trials that addressed the issue of
ate-acquired ISA. They reported that late-acquired ISA
ccurred more frequently with DES than BMS (odds ratio:
.49, 95% confidence interval: 1.15 to 5.35, p  0.02),
onsistent with the present study findings. However, they
emonstrated an increased risk of stent thrombosis in
atients with late-acquired ISA compared with those with
o ISA (odds ratio: 6.51, 95% confidence interval: 1.34 to
3
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4934.91, p  0.02) (3), contrary to the present study findings.
lthough these results are provocative, variations in defini-
ions, lesion characteristics, stent types, anti-platelet regi-
ens, and durations of follow-up in the individual studies
ight have influenced the findings in this meta-analysis.
urthermore, there might be a difference in associated vessel
all pathology, pathophysiology, and clinical consequences
etween the modest-sized, routinely-detected, late-acquired
SA (such as seen in the current study) and the large areas
f ISA reported in patients with very late stent thrombosis.
tudy limitations. The current study has certain limitations.
lthough the intended IVUS subsets represent the greater
ohort, they are derived only from centers specializing in
VUS and therefore are subject to some degree of selection
ias. Individual operators were not blinded to the IVUS at
he index procedure, and it is possible that optimization
trategies based on the IVUS images obtained might have
mpacted the incidence of early ISA. Despite this, the
nfluence of early ISA on clinical events would not be
ffected. Furthermore, not all IVUS datasets were accept-
ble for analysis—due to the aforementioned technical
ssues—and therefore, the incidence of late-acquired ISA
ight be overestimated or underestimated.
Additionally, the 96 cases of early ISA and 36 cases of
ate-acquired ISA represent, statistically, a relatively small
ample. As a result, with multivariable analyses, there exists
he potential for overfitting, and this could accentuate minor
uctuations in the results. These cases of ISA also do not
epresent patients initially presenting with AMI, in whom
he incidence of late-acquired ISA might be higher due to
hrombus dissolution. The low incidence of stent thrombo-
is seen across the TAXUS studies might also limit the
ower of this study to assess the impact of ISA on stent
hrombosis. Finally, this study only relates to BMS and
ES, and the ramifications of ISA in other stent platforms
re still somewhat undefined. Despite these limitations, the
esults from this analysis strongly suggest that ISA, whether
arly or late, is a relatively benign finding.
onclusions
n this multicenter analysis of the TAXUS IV, V, and VI
nd TAXUS ATLAS WH, LL, and DS studies, neither
outinely detected acute ISA nor routinely detected late-
cquired ISA in patients with TAXUS or BMS was
ssociated with adverse clinical events over a long-term
ollow-up.
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